Please assess the completion status of the following clinical trial:

Trial Title: A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Molecular diagnosis of CP CML of ≤ 6 months (from initial diagnosis).~2. Adequate hepatic, renal and pancreatic function.~3. Age ≥ 18 years.~Exclusion Criteria:~1. Any prior medical treatment for CML, including tyrosine kinase inhibitors (TKIs), with the exception of hydroxyurea and/or anagrelide treatment, which are permitted for up to 6 months prior to study entry (signature of ICF) if suitably approved for use in the subject's region.~2. Any past or current Central Nervous System (CNS) involvement, including leptomeningeal leukemia.~3. Extramedullary disease only.~4. Major surgery or radiotherapy within 14 days of randomization.~5. History of clinically significant or uncontrolled cardiac disease.~6. Known seropositivity to human immunodeficiency virus (HIV), current acute or chronic hepatitis B (hepatitis B surface-antigen positive), hepatitis C, cirrhosis or evidence of decompensated liver disease. Patients with resolved Hepatitis B can be included.~7. Recent or ongoing clinically significant GI disorder, e.g. Crohn's Disease, Ulcerative Colitis, or prior total or partial gastrectomy.~8. History of another malignancy within 5 years with the exception of basal cell carcinoma or cervical carcinoma in situ or stage 1 or 2 cancer that is considered adequately treated and currently in complete remission for at least l2 months.~9. Current, or recent (within 30 days, or 5 half-lives of investigational product) participation in other clinical trials of investigational agents and/or containing interventional procedures deemed contrary to the objectives and conduct of this trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bosutinib (Type: EXPERIMENTAL): Bosutinib, 400 mg, oral administration once a day
- Imatinib (Type: ACTIVE_COMPARATOR): Imatinib, 400 mg, oral administration once a day

Based on this trial design, predict the completion outcome and termination type (if applicable).